Literature DB >> 8097945

Mechanism of action of antimalarial drugs: inhibition of antigen processing and presentation.

R I Fox1, H I Kang.   

Abstract

Recent studies have elucidated the steps involved in the association of antigenic peptides with major histocompatibility complex (MHC) encoded proteins and have suggested how antimalarial compounds might influence this important site of immune activation. These steps of antigen presentation in the macrophage (or other antigen-presenting cells) include: (a) the partial proteolytic degradation of endogenous and exogenous proteins into peptides within the lysosome; (b) the synthesis of MHC class II (i.e. HLA-D associated) alpha, beta, and invariant (Ii) chains in the endoplasmic reticulum; (c) the initial association of alpha-Ii and beta-Ii chains in the endoplasmic reticulum and the transport of these complexes to the primary endosome; (d) the fusion of lysosomal vacuoles and endosomal vacuoles, allowing the mixtures of lysosomal enzymes, peptides, alpha-Ii and beta-Ii; (e) the displacement of Ii chains by peptides to form alpha-beta-peptide complexes in the endosome; and (f) the migration of alpha-beta-peptide complexes to the macrophage cell surface where they can stimulate CD4 T cells, resulting in release of cytokines. A low pH is required for digestion of the protein by acidic hydrolases in the lysosome, for assembly of the alpha-beta-peptide complex and for its transport to the cell surface. Chloroquine and hydroxychloroquine are weak diprotic bases that can diffuse across the cell membrane and raise the pH within cell vesicles. This background provides the underlying basis for the theory that antimalarials may act to prevent autoimmunity by the following putative mechanism.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8097945

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  19 in total

Review 1.  Combination therapy for autoimmune diseases: the rheumatoid arthritis model.

Authors:  N Fathy; D E Furst
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  Dendritic cells: potential triggers of autoimmunity and targets for therapy.

Authors:  J A Hardin
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

Review 3.  Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients.

Authors:  Michelle Petri
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

Review 4.  Histological and ultrastructural findings in chloroquine-induced cardiomyopathy.

Authors:  C August; H J Holzhausen; A Schmoldt; R Pompecki; S Schröder
Journal:  J Mol Med (Berl)       Date:  1995-02       Impact factor: 4.599

5.  Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers.

Authors:  Seyed Mostafa Monzavi; Aida Alirezaei; Zhaleh Shariati-Sarabi; Jalil Tavakol Afshari; Mahmoud Mahmoudi; Banafsheh Dormanesh; Faezeh Jahandoost; Ali Reza Khoshdel; Ali Etemad Rezaie
Journal:  Inflammopharmacology       Date:  2018-07-10       Impact factor: 4.473

6.  Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study.

Authors:  J Calvo-Alén; G McGwin; S Toloza; M Fernández; J M Roseman; H M Bastian; E J Cepeda; E B González; B A Baethge; B J Fessler; L M Vilá; J D Reveille; G S Alarcón
Journal:  Ann Rheum Dis       Date:  2005-11-03       Impact factor: 19.103

7.  Bordetella pertussis infection of primary human monocytes alters HLA-DR expression.

Authors:  Jennifer A Shumilla; Vashti Lacaille; Tara M C Hornell; Jennifer Huang; Supraja Narasimhan; David A Relman; Elizabeth D Mellins
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

Review 8.  Evidence-based therapy for cutaneous sarcoidosis.

Authors:  Christy B Doherty; Ted Rosen
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 9.  Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis.

Authors:  Alejandro Díaz-Borjón
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

10.  Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial.

Authors:  Daniel H Solomon; Rajesh Garg; Bing Lu; Derrick J Todd; Emileigh Mercer; Tabatha Norton; Elena Massarotti
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-08       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.